HENRY SCHEIN INC (HSIC) stock intrinsic value fair value estimate & owner earnings analysis

Henry Schein is one of the two largest distributors of dental and medical supplies and equipment to independent practices, reporting through three segments: Global Distribution and Value-Added Services (consumables, equipment and services), Global Specialty Products, and Global Technology (practice-management software). It was cut down to its present shape when the Animal Health business was spun off in February 2019, so this analysis uses the six full years since (2020 to 2025). Revenue was $13.2 billion in 2025, up about 30% from 2020. What the business earns. We measure the cash the whole business produces before paying lenders: cash from operations, less working-capital swings, less stock compensation, less the capital spending needed to keep the business running (including capitalized software, which we count as a real recurring cost), plus cash interest paid. That figure was $598 million in 2020, $772 million in 2021, $751 million in 2022, $648 million in 2023, $618 million in 2024 and $687 million in 2025, a median of $667 million. Two things flatter the window and two depress it: 2021 and 2022 carried pandemic-era demand and 2020 stock compensation was unusually low ($9 million), while 2023 and 2024 were depressed by the October 2023 cyber incident that disrupted North American and European distribution. We kept all six years because the distortions run in both directions; leaving out the pandemic-boosted years would lower the starting figure by about 5%. 2025 included roughly $20 million of insurance recoveries from the cyber incident, and 2024 about $40 million, which we did not treat as recurring. Net income including minority partners ran $8 to $21 million a year above net income attributable to Henry Schein shareholders; that gap is the minority partners' share and is now reconciled. Growth. Business cash flow grew 11% in 2025, but that was largely the rebound from the cyber-depressed 2024 and not a new run rate. For the first year of the base case we assume 3% growth from the typical level, which lands at about $687 million, essentially where 2025 finished, so year one is below the 2025 actual. First-half 2026 operating income rose 8% ($353 million versus $326 million), which supports not going lower. Beyond that we credit only what the record proves: over 2020 to 2025 this cash flow grew about 2.8% a year while revenue grew 30%, through a pandemic and a major cyber incident. We taper growth to zero by year ten and then hold earnings flat. We did not credit faster software growth, share gains, or earnings from future acquisitions (the company spent $392 million on acquisitions in 2025 and $284 million in 2023, but that spending is not deducted in our earnings measure, so counting the earnings it buys would count growth that has not been paid for). We also did not count share buybacks as growth. The share count fell from about 143 million in 2020 to about 111 million by mid-2026, but the company bought back $850 million of stock in 2025 and $325 million in the first half of 2026 while short-term borrowings rose about $260 million in those six months, so part of the per-share growth in prior years has been borrowed. What the shares are worth after the lenders. About 57% of the base case's business value sits beyond year ten, resting on a distribution network, customer relationships and a software base that have kept earning for decades with the reinvestment already charged. Net of what is owed, per diluted share (about 112.7 million): Base case: the business is worth about $112 per share. It owes about $30 per share in borrowings (long-term debt of roughly $2.3 billion plus about $1.0 billion of short-term borrowings and receivables financing at June 27, 2026) and about $14 per share to minority partners in subsidiaries whose cash flow is counted in full here ($660 million of minority interests plus $906 million of redeemable minority interests, the latter carried at fair value). The difference is about $69 per share. Bull case: about $154 per share for the business, less the same $44 of claims, leaves about $110. It assumes the levers already visible in the filings execute: restructuring programs under way since 2022 and 2024, software revenue growing faster than distribution, and tuck-in acquisitions at the pace of recent years. Cash flow grows 6% in year one, tapering to 2% by year ten, then 1% a year. Bear case: about $88 per share for the business, less $44, leaves about $44. It repeats the 2022 to 2024 episode, when this cash flow fell 18% in two years, starting next year and lasting two years, and then recovers only to 90% of today's typical level and stays there, reflecting the buying groups and dental service organizations the company itself describes as emphasizing competitive prices, plus the Medicaid funding reductions flagged in the 2025 filing. Even here, cash flow covers interest more than three times over, so the company can carry its debt. Debt maturities (as of December 2025: $534 million in 2027, $221 million in 2028, $143 million in 2029 and $810 million in 2030) are spread across years rather than concentrated, but the amount of borrowing has risen: long-term debt grew from $1.89 billion to $2.34 billion during 2025, and interest paid went from $43 million in 2020 to $151 million in 2025. What changed since our previous analysis. Our earlier figures ($70 / $117 / $160) were prepared on a different basis and are not comparable. In terms of the business: borrowing has continued to climb alongside buybacks, the cyber incident is now well behind the company, and first-half 2026 operating income is growing. We also note that the earlier text cited the buying-group trend as a risk the company discloses; the company's own filing describes it as a trend that tends to favor large, broad-line distributors, so we treat it as a partial drag in the bear case, not as a base-case headwind. A strategic partnership with KKR (two board seats and an ownership standstill that now allows up to 19.9% of the shares) is also a factor in how the company allocates capital. What would make this wrong. If the pandemic-boosted years are excluded the base case falls to about $63. If the business can credibly grow 1% a year indefinitely after year ten the base rises to about $82. If the minority partners' claim is closer to the redeemable portion alone, the base is about $74. Tariffs did not materially affect 2025 results, and the Supreme Court has since invalidated many of them, but the company says their future is unclear. Margin-of-safety price: about $48 per share. We are reasonably sure of the earnings level, since six years spanning a pandemic and a major cyber incident stayed between $598 million and $772 million, but the shares are a leveraged claim: about $4.9 billion sits ahead of the common stock, so a 10% change in annual business cash flow moves the value by roughly $11 per share. The worst plausible event is another cyber or operational disruption while borrowings are high, or a faster migration of customers to buying groups. The company would survive either, given its interest coverage and staggered maturities, but shareholders could see value near the bear case. The company pays no dividend; cash goes to buybacks and debt, so any return comes entirely from the value building up inside the business. The price assumes about a three-year holding period. From $48, if the base case plays out and cash flow retires debt, the shares would be worth about $85 in three years, which implies about 20% a year; in the bear case the shares would be worth roughly $56 in three years, still above the margin-of-safety price.